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Abstract
Background: Patients undergoing salvage surgery for recurrent head and neck squamous cell carcinoma are at
high risk of postoperative complications due to the adverse effects of radiotherapy on wound healing. Malnutrition
is an additional risk factor and we tested the hypothesis that preoperative administration of immunonutrition
would decrease complications in this high risk population.
Methods: This single armed study with historical control included consecutive patients undergoing salvage surgery
for recurrent head and neck squamous cell carcinoma. We compared outcomes before and after implementation of
preoperative immunonutrition and adjusted the regression analysis for gender, age, body mass index, Nutritional
Risk Screening (NRS 2002), tobacco and alcohol consumption, tumor localization, tumor stage, and type of surgery.
The primary endpoint was overall complications from surgery within a follow-up of 30 days.
Results: Ninety-six patients were included (intervention group: 51, control group: 45). Use of preoperative
immunonutrition was associated with a significant reduction in overall complications (35% vs. 58%, fully-adjusted
odds ratio 0.30 (95%CI 0.10–0.91, p = 0.034). Length of hospital stay was also significantly reduced (17 days vs. 6
days, p = < 0.001). No differences in mortality and hospital readmission were found. These results remained robust
in multivariate analysis.
Conclusions: In patients undergoing salvage surgery for recurrent head and neck squamous cell carcinoma,
preoperative immunonutrition exhibited favorable effects on the complication rate and consequently reduced the
length of hospital stay. By improving both tissue regeneration and immune response, immunonutrition may help to
improve surgical outcomes in this high-risk population.
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Background
Surgery, radiotherapy (RT) and chemo-radiotherapy (CRT)
are mainstays of treatment for head and neck squamous
cell carcinoma (HNSCC). Although an effective treatment,
(C)RT has significant side effects on local tissues. Fibrosis
caused by fibroblast dysfunction and alterations in blood
perfusion through microvascular damage lead to impaired
wound healing and predispose for local complications [1].
Other side effects such as pain, dysgeusia, xerostomia,
vomiting, and inappetence may cause malnutrition, which
is an additional independent risk factor for wound healing
[2, 3]. Malnutrition, defined as nutrition imbalance leading
to weight loss, reduced muscle mass and subcutaneous fat,
as well as diminished functional status [4], is a common
condition in patients suffering from HNSCC, as these
tumors cause aggravation of catabolism and impairment of
deglutition through mechanical obstruction or infiltration
of the muscles of the tongue and pharynx. Excessive alco-
hol consumption, a known risk factor for HNSCC, may
further impair the nutritional status [5, 6].
Given these unfavorable conditions, patients with HNSCC
undergoing salvage surgery for tumor persistence/
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recurrence or second primaries are at high risk for
postoperative complications, with a total incidence of 40–
60% described in the literature [7–11]. Complications
include wound infections, orocutaneous and pharyngocu-
taneous fistulas, respiratory insufficiency, pneumonia, and
septicemia. Length of hospital stay (LOS) may subse-
quently be extended and prognosis impaired [12].
Current evidence suggests that perioperative immuno-
nutrition (IN) may reduce complications and LOS after
surgery [13]. An intact immune response is crucial for
recovery after surgery and especially wound healing. How-
ever, it may be compromised by tumor-associated im-
munosuppression [14] and surgical interventions, which
after the initial pro-inflammatory phase cause a propor-
tionate immunosuppressive phase [15]. Malnutrition leads
to a deficiency of essential nutrients needed for cell repli-
cation, such as nucleotides, amino acids, fatty acids, bases,
phosphate and metal ions, and weakens the immune sys-
tem additionally. The concept of perioperative IN is to
provide the essential nutrients to promote an adequate
immune response after surgery. Immunonutrition are
medical dietary formulas designed to provide the essential
nutrients for an adequate immune reaction during med-
ical treatment, such as surgical interventions. Although
the bulk of clinical data stems from trials in abdominal
surgery [16, 17], a few studies including our own recently
published analysis of 411 patients are supporting this con-
cept for surgery in HNSCC [12, 18–22]. However, none of
these studies have focused on the especially vulnerable pa-
tients undergoing salvage surgery after (C)RT, and the aim
of this study was to evaluate the effect of preoperative IN
on postoperative complications this high risk population.
Methods
Study design and population
The study was conducted in accordance with the 1957
Declaration of Helsinki, and the protocol was approved by
the Ethics Committee of the Canton of Bern, Switzerland
(Ref. no. 256/2015).
This is a single armed study with a historical control
cohort and included patients undergoing salvage surgery
for persistent/recurrent or second primary HNSCC after
curatively intended RT, CRT or RT with concomitant
immunotherapy (Cetuximab) for tumors arising in the
oral cavity, oropharynx, hypopharynx, and larynx, as well
as carcinoma of unknown primary (CUP) of the neck.
All tumor stages were included. Conformal 3D, intensity
modulated or volumetric modulated arc radiotherapy
techniques were used for initial treatment. Patients were
excluded if the (C)RT did not affect the operative field
of salvage surgery with more than 50 Gray. Diabetes or
treatment with immunosuppressive drugs did not lead
to exclusion. The intervention group receiving IN in-
cluded consecutive patients treated between July 2012
and September 2016. Immunonutrition was introduced
in January 2012, but compliance was not monitored
during the first 6 months and therefore, patients treated
in this period were excluded. The control group who did
not receive IN included consecutive patients treated be-
tween July 2008 and December 2011. Both groups were
treated according to internal guidelines of our tertiary
university hospital by multiple surgeons of the same
surgical team.
All evaluated surgical salvage procedures were per-
formed with curative intent and based on institutional
tumor board decision.
Preoperative body mass index (BMI) and nutritional sta-
tus were assessed using the Nutritional Risk Screening
2002 (NRS 2002) [23] score. NRS 2002 takes into account
patients’ weight loss, BMI, food intake, severity of disease,
and age. The score ranges from 0 (no nutritional risk) to 6
(high nutritional risk), and in a non-study setting, nu-
tritional support is recommended for patients with
scores ≥3. For patients receiving IN, these parameters were
assessed prior to IN administration. Socio-demographic
data, concomitant diseases and risk factors (smoking, alco-
hol overconsumption), and tumor specific data were re-
corded from hospital charts. All RT plans were reviewed to
assess total radiation dose to the tissue in the operative
field. The TNM system (International Union against Cancer
UICC 7th edition) [24] was used for staging of disease.
Immunonutrition regimen
The IN used in this study was Oral Impact® (Nestlé
Health Science, Vevey, Switzerland), which has been
used in various studies including healthy as well as
cancer patients and has shown to be safe [25, 26]. One
unit (74 g powder to be dissolved in 250 ml of water)
provides 300 kcal, and contains 16.8 g protein, 8.3 g fat,
and 40.2 g carbohydrates. The sip feed is enriched with
omega-3 fatty acids (1.0 g/unit), arginine (3.8 g/unit),
RNA-nucleotides (0.39 g/unit) and soluble guar fiber
(3 g/unit). Patients in the intervention group received
3 units per day for 5 days before surgery. For monitor-
ing of compliance, patients tagged each consumed
dose on a form collected on the day of surgery, and
missing data were completed via telephone call.
Endpoints
The primary endpoint was defined as overall wound
complications within the first 30 days after surgery. The
total number of patients with wound complications was
recorded, and wound complications were also catego-
rized into the following groups: wound dehiscence, ab-
scess, fistula, hematoma, hemorrhage, seroma, and flap
necrosis. Additionally, the severity of local complications
was graded according to the Buzby classification [27].
Furthermore, the Dindo classification [28] was applied,
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which captures and grades both local and systemic compli-
cations. Complications were recorded regardless whether
they occurred during or after hospitalization, as long as
they arose within the first 30 days after surgery. Length of
total hospital stay was defined as the total number of days
spent in hospital after surgery, including readmissions.
General criteria for discharge were mobilization, no on-
going wound issues, sufficient nutritional intake, and
assured aftercare. Data were recorded retrospectively
via chart review by a postgraduate and checked for ac-
curacy by senior staff member of the Department of
Oto-Rhino-Laryngology, Head and Neck Surgery.
For subgroup analysis, we defined extensive surgery as
open tumor resection with or without neck dissection
and with or without flap reconstructions. Restricted sur-
gery was defined as transoral resection with or without
neck dissection or neck dissection alone.
Compliance to the IN regimen was measured as the
percentage of the total planned intake that was ad-
ministered correctly, and four subgroups were formed
(0–24%, 25–49%, 50–74%, 75–100%).
Statistical analysis
Categorical variables are presented as percentages (num-
bers), and continuous variables are presented as medians
(interquartile range, IQR) or 95% confidence intervals
(CI) where applicable. The chi-square (Wald) test was
used for frequency comparisons and two-group compar-
isons were assessed with the Mann-Whitney U-test. Uni-
variate and multivariate regression analyses were applied
to determine the effect of IN on the primary endpoint
and secondary endpoints. To better assess IN’s impact
on the endpoints in this non-randomized setting and to
account for possible confounders, we calculated a multi-
variate regression model adjusted for gender, age, body
mass index, NRS 2002 [23], tobacco and alcohol con-
sumption, tumor localization, tumor stage, type of sur-
gery, flap reconstruction and comorbidities. To evaluate
subgroup effects, we assessed effect modification by
including interaction terms into our statistical models.
Results were considered statistically significant if p < 0.05.
Correlations were calculated using Pearson’s or Spear-
man’s correlation coefficients when needed. The statis-
tical analysis was performed on IBM SPSS Statistics
for Windows (IBM Corp., 2010, Version 19.0. Armonk,
New York, USA) and STATA 12.1 (StataCorp LP,
2011, Texas, USA) software.
Results
One hundred and five patients were evaluated, of which
nine were excluded because RT did not affect the opera-
tive field, leaving 96 patients undergoing salvage surgery
for persistent/recurrent HNSCC or second primaries
after (C)RT. Fifty-one received IN, while the control
group included 45 patients. Immunonutrition was ad-
ministered orally in 41 patients (80%) and via previously
inserted percutaneous endoscopic gastrostomy tube in
10 patients (20%). Socio-demographic and clinical char-
acteristics are summarized in Table 1.
Both groups showed similar distributions of sex, age,
risk factors, and preoperative BMI. The proportion of
patients with an NRS 2002 [23] ≥3 was higher in the
intervention group, but the difference was not statisti-
cally significant. Flap reconstruction was preformed in
23 patients who received IN (45%, 19 pedicled and 4 free
flaps) and 18 patients of the control group (33%, 11 ped-
icled and 4 free flaps; p = 0.24). Number of tracheosto-
mies, feeding modality and administration of peri
−/postoperative antibiotics were not statistically signifi-
cant different between the two groups (Table 1).
Complications are shown in Table 2. The total number
of patients suffering any complications was significantly
lower in the group receiving IN (35% vs. 58% in the con-
trol group, p = 0.027). As shown in Table 2, this reduc-
tion remained robust (adjusted OR 0.28, p = 0.049) in
the multivariate model adjusted for socio-demographics,
risk factors, tumor characteristics, type of surgery, flap
reconstruction, and comorbidities. A decrease was ob-
served in all subcategories of complications (wound dehis-
cence, wound abscess, fistula, and hematoma/hemorrhage/
seroma), but the differences on subcategory level were not
statistically significant. The total number of patients
with local complications was not statistically different
between the two groups (control group: 22% vs. inter-
vention group: 18%, p = 0.57).
The severity of the complications as graded by the
Buzby [27] and Dindo [28] classification did not show
significant differences between the two groups (Table 3).
There were no fatalities in either group within the first
30 days after surgery.
Secondary outcome analysis showed a significant re-
duction in LOS in the IN group (adjusted difference −
11.36 days, (95%CI − 20.08 to − 2.63), median 6 (mean
11.5) days vs. 17 (mean 24.2) days in the control group,
p = < 0.001), while the rate of readmissions was similar
in both groups (Table 4 and Fig. 1). Total or partial flap
necrosis and surgical interventions due to complications
were similar in both groups. These results remained ro-
bust after multivariate analysis (Table 4). Table 5 shows
compliance in the IN group; 84.3% of patients took over
75% of the prescribed nutrition. The subgroups were too
small to allow a statement on the correlation between
compliance and outcome parameters.
Discussion
To our knowledge, this is the first study investigating
the effect of preoperative IN on short-term outcomes
after salvage surgery in previously irradiated patients
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Table 1 Socio-demographic and medical characteristics
Characteristics Total
n = 96
Control
n = 45
Intervention
n = 51
p-value
Mean age, years (SD) 65.4 (10.56) 65.4 (10.0) 65.5 (11.1) 0.97
Gender
Male 76 (79%) 35 (78%) 41 (80%) 0.75
Female 20 (21%) 10 (22%) 10 (20%)
Smoking
No 24 (25%) 11 (24%) 13 (25%) 0.11
Active 33 (34%) 20 (44%) 13 (25%)
Ceased 39 (41%) 14 (31%) 25 (49%)
Smoking (pack years), median (IQR) 45 (30, 60) 47.5 (30, 68) 42.5 (38, 60) 0.88
Alcohol
No 43 (45%) 20 (44%) 23 (45%) 0.99
Active 42 (44%) 20 (44%) 22 (43%)
Ceased 11 (11%) 5 (11%) 6 (12%)
Alcohol (glass/week), median (IQR) 14 (6,42) 18 (4,70) 14 (6,40) 0.53
Body mass index at admission, mean (SD) 23.29 (3.95) 23.84 (3.84) 22.80 (4.03) 0.21
Nutritional Risk Screening 200224
Score< 3 78 (81%) 40 (89%) 38 (75%) 0.21
Score≥ 3 18 (19%) 5 (11%) 13 (25%)
Comorbidities
Diabetes mellitus 10 (10%) 6 (13%) 4 (8%) 0.38
Hepatopancreatic disease 6 (6%) 2 (45) 4 (8%) 0.49
Cardiovascular disease 57 (59%) 25 (56%) 32 (63%) 0.47
Pulmonary disease 16 (17%) 7 (16%) 9 (18%) 0.78
Other diseases 25 (26%) 8 (18%) 17 (33%) 0.08
Immunosuppression
(drug induced)
1 (1%) 0 (0%) 1 (2%) 0.35
Type of tumor
Persistence/recurrence 76 (79%) 34 (76%) 42 (82%) 0.41
Second primaries 20 (21%) 11 (24%) 9 (18%)
Localization
Oral cavity 30 (31%) 18 (40%) 12 (24%) 0.35
Oropharynx 20 (21%) 7 (16%) 13 (25%)
Hypopharynx 9 (9%) 5 (11%) 4 (8%)
Larynx 25 (26%) 11 (24%) 14 (27%)
Lymph node recurrence 12 (13%) 4 (9%) 8 (16%)
UICC-stage of recurrent/persistent tumors and second primaries
I 21 (22%) 11 (24%) 10 (20%) 0.55
II 25 (26%) 12 (27%) 13 (25%)
III 21 (22%) 7 (16%) 14 (27%)
IV 29 (30%) 15 (33%) 14 (27%)
Type of surgery
Restricted 44 (46%) 17 (38%) 27 (53%) 0.14
Extensive 52 (54%) 28 (62%) 24 (47%)
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with HNSCC. Our results show a significant reduction
in the number of patients suffering complications (35%
vs. 58%), in the group with IN intake before salvage sur-
gery. Compared to other studies on the incidence of
complications after salvage surgery without IN, who re-
ported rates of 41–61% [7–11], complications in the IN
group (35%) in our study were low.
Our results also showed that patients receiving IN had
significantly lower LOS (6 days vs. 17 days), which is in
line with several other authors for both gastrointestinal
and head and neck surgery [16, 17, 22, 29–32]. This reduc-
tion may be attributable in part to the lower rate of compli-
cations in the IN group, but seems out of proportion
compared to the reduction of complications. Other pos-
sible underlying causes for prolonged LOS such as age
(leading to slower rehabilitation), tumor localization, type
of surgery and flap reconstruction in particular, as well as
comorbidities, were considered in the multivariate analysis,
Table 2 Effects of immunonutrition on postoperative complications and multivariate analysis
Endpoint Control Intervention p-
value
Multivariate modelb
n = 45 n = 51 Adjusted OR (95%CI) p-value
Number of patients with local or systemic complications 26 (58%) 18 (35%) 0.027 0.28 (0.08 to 1.00) 0.049
Local complicationsa
Wound dehiscence 9 (20%) 7 (14%) 0.41 0.60 (0.03 to 1.44) 0.11
Wound abscess 7 (16%) 6 (12%) 0.59 0.24 (0.02 to 3.09) 0.28
Fistula 8 (18%) 5 (10%) 0.25 0.64 (0.03 to 14.1) 0.77
Local hematoma, hemorrhage, seroma 5 (11%) 5 (10%) 0.83 0.20 (0.02 to 2.08) 0.18
aMore than 1 complication possible per patient. bThe multivariate model is adjusted for gender, age, body mass index, Nutritional Risk Screening 2002 [23],
smoking habit, alcohol habit, tumor localization, tumor stage, type of surgery, flap reconstruction, and comorbidities. P-values shown in bold indicate significance
Table 1 Socio-demographic and medical characteristics (Continued)
Characteristics Total
n = 96
Control
n = 45
Intervention
n = 51
p-value
Flap reconstruction
No 58 (60%) 30 (67%) 28 (55%) 0.24
Yes 38 (40%) 15 (33%) 23 (45%)
Tracheostomy
Yes 25 (11%) 15 (33%) 10 (20%) 0.16
No 71 (89%) 30 (66%) 41 (80%)
Long-term tracheostomy after surgery > 30 days
Yes 11 (11%) 7 (16%) 4 (8%) 0.33
No 85 (89%) 38 (84%) 47 (92%)
Feeding modality before surgery
Oral 79 (82%) 38 (84%) 41 (80%) 0.42
NG tube 1 (1%) 1 (2%) 0 (0%)
PEG tube 16 (17%) 6 (13%) 10 (205)
Feeding modality after surgery
Oral 29 (30%) 12 (27%) 17 (33%) 0.28
NG tube 43 (45%) 24 (53%) 19 (37%)
PEG tube 24 (25%) 9 (20%) 15 (29%)
Peri−/postoperative antibiotic treatment
Yes 92 (96%) 43 (96%) 49 (96%) 0.90
No 4 (4%) 2 (4%) 2 (4%)
Duration (days) of peri−/postoperative antibiotic treatment, median (IQR) 12 (10, 16.5) 12 (10, 19) 13 (11, 15) 0.82
Maximum RT dose to operative field (Gray), median (IQR) 70 (66,72) 67 (61, 72) 72 (66, 72) 0.09
Time RT to surgery (days), median (IQR) 524 (231,1645) 874 (311, 1993) 436 (202, 1276) 0.05
IQR interquartile range, NG nasogastric, PEG percutaneous endoscopic gastrostomy, RT radiotherapy, SD standard deviation, UICC Union of International Cancer
Control [24]
Mueller et al. Journal of Otolaryngology - Head and Neck Surgery           (2019) 48:25 Page 5 of 9
but the significance of the reduction in LOS remained ro-
bust. Another possible factor that was not included in the
multivariate analysis is the slightly higher rate of perman-
ent tracheostomies in the control group (Table 1), but the
tracheostomy rate only varied insignificantly (p = 0.16), and
we consider it unlikely to be the driving force behind lon-
ger LOS in the control group. Complications due to PEG
tube insertions could also potentially prolong hospital stay,
but while the rate of postoperative feeding tube (PEG and
NG tube) was similar in both groups, PEG tubes were ac-
tually slightly less common in the control group (Table 1),
and therefore not associated with the longer LOS of the
control group. More likely, the results on LOS may be par-
tially biased because of the historical nature of the control
cohort and in particular, the introduction of the diagnosis
related groups system in Switzerland (SwissDRG) in 2012.
SwissDRG penalizes prolonged hospital stays and has led
to optimization of the discharge process of patients. This
may have contributed partially to shorter LOS in the IN
group, who were treated after 2012.
The effect of IN on surgical outcomes has been stud-
ied more extensively in gastrointestinal surgery, and two
large meta-analyses on the impact of IN were published
in 2012, including a combined 29 controlled randomized
trials [16, 17]. Both studies concluded that IN reduces
infectious and non-infectious postoperative complica-
tions and LOS. Guidelines of both the European and
American Society of Parenteral Nutrition therefore rec-
ommend IN for at least all malnourished patients under-
going major abdominal surgery [33, 34].
Scientific data on the effects of IN in head and neck
surgery is much less definite, primarily due to the lim-
ited number of large prospective randomized controlled
trials [35]. Moreover, several of the so far published trials
reported significant problems with compliance to the
prescribed diets [20, 22]. In their systematic review of 10
trials investigating the effect of arginine-based IN on
postoperative outcomes in head and neck cancer, Stable-
forth et al. [35] report that LOS was reduced by 3.5 days
in groups receiving IN compared to standard formula or
control. The reasons for this reduction remain unclear
since it does not necessarily correlate with the complica-
tion rates of the analyzed trials. Several trials reported a
lower rate of infectious complications [20, 22], wound
infections/complications [22, 36], and fistula formation
[29–31, 37]. These findings are contested by other trials
which found no differences in postoperative complica-
tions at all [32, 38]. None of these studies report results
Table 3 Number and grading of complications according to the Buzby [27] and Dindo [28] classifications
Grade Definition Control
n = 45
Intervention
n = 51
p-value
Buzby classification (local complications) [27]
I Redness, swelling, wound not opened 0 (0%) 1 (2%) 0.27
II As Grade I, but wound opened, dehiscence 5 (11%) 3 (6%)
III Pus visible in wound 5 (11%) 3 (6%)
IV Fasciitis with surgical debridement 0 (0%) 2 (4%)
Dindo classification (local and systemic complications) [28]
I Any deviation from the normal postoperative course without the need
of pharmacological treatment or surgical, endoscopic, or radiological intervention
8 (18%) 5 (10%) 0.52
II Requiring pharmacological treatment 11 (24%) 5 (10%)
III Requiring surgical, endoscopic, or radiological intervention 5 (11%) 7 (14%)
IV Life-threatening complication requiring intensive care management 2 (4%) 1 (2%)
V Death of patient 0 (0%) 0 (0%)
Table 4 Effect of immunonutrition on length of hospital stay and other secondary outcome parameters
Endpoint Control Intervention p-value Multivariate modela
n = 45 n = 51 Adjusted OR (95% CI) p-value
Total LOS, median (IQR) 17 (8, 28) 6 (3, 16) < 0.001 −11.36 (−20.08 to − 2.63) 0.011
Flap total or partial necrosis 1 (7%) 2 (9%) 0.83 – –
Surgery due to complications 8 (18%) 10 (20%) 0.82 0.45 (0.06 to 3.44) 0.44
Readmissions 4 (9%) 4 (8%) 0.85 0.17 (0.01 to 3.82) 0.27
Mortality within 30 days 0 (0%) 0 (0%) – – –
aThe multivariate model is adjusted for gender, age, body mass index, Nutritional Risk Screening 2002 [23], smoking habit, alcohol habit, tumor localization, tumor
stage, type of surgery, flap reconstruction, and comorbidities. P-values shown in bold indicate significance. LOS length of hospital stay, IQR interquartile range
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for patients previously treated with RT. In their pro-
spective randomized, double-blind study, Falewee et al.
[22] included patients who had received previous RT
when it was concluded more than 1 year before the trial,
but no subgroup analysis was reported. The other stud-
ies focusing on HNSCC either excluded patients with
previous RT [21] or did not specify whether such pa-
tients were included [12, 29–32, 36–38].
Radiotherapy increases the risk of wound healing
problems. Microvascular damage and activation of co-
agulation lead to reduced blood flow in irradiated tissue
[1, 39]. The resulting hypoxia induces proliferation of
subendothelial connective tissue in small arteries leading to
narrowing and obliteration of the vessel lumen, aggravated
additionally by thrombosis [40, 41]. The second critical
factor is fibrosis, which is particularly strong in the cutis
and subcutis [1], where dysfunctional fibroblasts produce
excess extracellular matrix that irreversibly replaces normal
elastic and collagen fibers and adipose tissue. The resulting
tissue is thus hypoxic, hypovascular and hypocellular and
the overlying skin suffers atrophy marked by thinning and
loss of adnexal structures [41]. Hypovascularity and
hypoxia continue to impede physiological wound healing
even years after RT and make the affected tissues more
susceptible for bacterial infections [42]. This risk is further
elevated in case of arginine deficiency, which weakens the
immune response by inhibiting T-cell proliferation. The
underlying mechanism is a reduction in a ζ-chain compo-
nent of the T-cell receptor, which is also reduced by certain
cancers and after surgery [43]. Furthermore, in activated
myeloid cells, arginine is metabolized by the enzymes indu-
cible nitric oxide synthase (iNOS) and arginase 1. The
former generates nitric oxide NO, which is indispensable
in fighting infections. The latter produces ornithine, a
crucial precursor in collagen synthesis [44–46]. Omega 3
fatty acids may inhibit collagen deposition, minimize scar
formation and reduce wound infections [25]. Thus, defi-
ciencies in arginine and omega 3 fatty acids impair the im-
munological response to infections as well as the wound
healing process, and potentiate the long term tissue effects
of RT. Given this background, it seems conceivable that
supplementation of arginine and omega 3 fatty acids may
have a marked impact in preventing complications of pa-
tients undergoing salvage surgery after RT.
Limitations
This study is limited by its retrospective character, the fact
that it used a historical control group, and the limited
number of patients. To account for the possible con-
founders inherent to this study design, we conducted the
multivariate analysis, in which the results remained robust
(Tables 2 and 3). As discussed earlier, the disproportionate
reduction in LOS in the group receiving IN may be par-
tially biased due to the historical nature of the control co-
hort and the introduction of the diagnosis related groups
system in Switzerland (SwissDRG) in 2012, leading to
optimization in the discharge process of patients.
Interestingly, the median maximum dose of radiation to
the operative field was higher in the IN group (p = 0.09,
Table 1), and the median interval between radiation and
salvage surgery was shorter (p = 0.05, Table 1). However,
the maximum radiation dose to any part of the tissue
within operative field is not representative of the total or
mean dose to this tissue. The exact calculation of the mean
radiation dose to the operative field is inherently difficult if
not impossible, since salvage surgery is not performed along
radiation fields and will always involve areas of tissue irradi-
ated at variable doses (or not at all). Any conclusion on the
correlation of IN, radiation dose, and complication rates
based on our data would therefore be highly speculative.
Conclusions
In patients undergoing salvage surgery for persistent/re-
current HNSCC and second primaries after initial RT,
Fig. 1 Length of hospital stay. Box plot comparing length of
hospital stay between the group that received immunonutrition
before salvage surgery and the control group (p < 0.001)
Table 5 Compliance with planned intake of immunonutrition
RRI/TPI
a No. of patients
0–24% 2 (3.9%)
25–49% 1 (2.0%)
50–74% 5 (9.8%)
75–100% 43 (84.3%)
a Ratio = Real intakeTheoretically planned intake ×100
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preoperative IN is associated with a reduction of the
overall complication rate and consequently decreased
the LOS. Our results suggest that preoperative IN may
be of particular benefit in this high-risk population, as
its effects may improve tissue regeneration and immune
response, which are two main reasons for impaired
wound healing and infectious complications after (C)RT.
Prospective randomized trials are necessary to deliver
definite evidence to justify the systematic perioperative
use of IN in surgery for HNSCC and based on the re-
sults of our study, we strongly recommend stratified
randomization.
Abbreviations
BMI: Body mass index; CRT: Chemo-radiotherapy; HNSCC: Head and neck
squamous cell carcinoma; IN: Immunonutrition; LOS: Length of hospital stay;
NG: Nasogastric (feeding tube); NRS: Nutritional risk screening;
PEG: Percutaneous endoscopic gastrostomy; RT: Radiotherapy
Acknowledgments
Thanks are extended to Anita La Marra and Barbara Stucki of the
Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Inselspital
for their support.
Funding
The study was funded by the research funds of the Department of Diabetes,
Endocrinology, Clinical Nutrition and Metabolism, and the Department of
Oto-Rhino-Laryngology, Head and Neck Surgery, and the Inselspital, Bern
University Hospital and University of Bern, Switzerland. The latter fund re-
ceived a grant from Nestlé Health Science (Vevey, Switzerland), to partially
support the research activity concerning this study.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
SAM oversaw data collection and verification, was responsible interpretation
of results, and writing of the manuscript. CM was responsible for data
collection and interpretation of results. BB reviewed the RT plans of all
patients. CA made major contributions to data collection. PS was responsible
for the statistical concept and analysis. ZS and RG were responsible for the
study conception, data interpretation and made major contributions to the
manuscript. All authors have read and approved the final version of the
manuscript.
Ethics approval and consent to participate
The study was conducted in accordance with the 1957 Declaration of
Helsinki, and the protocol was approved by the Ethics Committee of the
Canton of Bern, Switzerland (Ref. no. 256/2015).
Consent for publication
Not applicable.
Competing interests
The research fund of the Department of Oto-Rhino-Laryngology, Head and
Neck Surgery received a grant from Nestlé Health Science (Vevey,
Switzerland), to partially support the research activity concerning this study.
Nestlé Health Science was not involved at any phase of the study, and has
had no insights in the studies outcomes or the manuscript prior to
publication.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Oto-Rhino-Laryngology, Head and Neck Surgery Inselspital,
Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
2Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism
Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
3Department of Radiation Oncology Inselspital, Bern University Hospital,
University of Bern, 3010 Bern, Switzerland. 4Department of Endocrinology,
Diabetes and Clinical Nutrition University Department of Internal Medicine,
Kantonsspital Aarau, 5001 Aarau, Switzerland.
Received: 21 August 2018 Accepted: 16 May 2019
References
1. Dormand E-L, Banwell PE, Goodacre TEE. Radiotherapy and wound healing.
Int Wound J. 2005;2:112–27.
2. Robbins KT, Favrot S, Hanna D, Cole R. Risk of wound infection in patients
with head and neck cancer. Head Neck. 1990;12:143–8.
3. Ravasco P, Monteiro-Grillo I, Camilo ME. Does nutrition influence quality
of life in cancer patients undergoing radiotherapy? Radiother Oncol.
2003;67:213–20.
4. White JV, Guenter P, Jensen G, Malone A, Schofield M. Academy
malnutrition work group, et al. consensus statement: academy of nutrition
and dietetics and American Society for Parenteral and Enteral Nutrition.
J Parenter Enter Nutr. 2012;36:275–83.
5. Farsi NJ, Rousseau M-C, Schlecht N, Castonguay G, Allison P, Nguyen-Tan PF,
et al. Aetiological heterogeneity of head and neck squamous cell
carcinomas: the role of human papillomavirus infections, smoking and
alcohol. Carcinogenesis. 2017;38:1188–95.
6. Ross LJ, Wilson M, Banks M, Rezannah F, Daglish M. Prevalence of
malnutrition and nutritional risk factors in patients undergoing alcohol and
drug treatment. Nutrition. 2012;28:738–43.
7. Nichols AC, Kneuertz PJ, Deschler DG, Lin DT, Emerick KS, Clark JR, et al.
Surgical salvage of the oropharynx after failure of organ-sparing therapy.
Head Neck. 2011;33:516–24.
8. Kadota H, Fukushima J, Nakashima T, Kumamoto Y, Yoshida S, Yasumatsu R,
et al. Comparison of salvage and planned pharyngolaryngectomy with
jejunal transfer for hypopharyngeal carcinoma after chemoradiotherapy.
Laryngoscope. 2010;120:1103–8.
9. Taki S, Homma A, Oridate N, Suzuki S, Suzuki F, Sakashita T, et al. Salvage
surgery for local recurrence after chemoradiotherapy or radiotherapy in
hypopharyngeal cancer patients. Eur Arch Otorhinolaryngol. 2010;267:1765–9.
10. Weber RS, Berkey BA, Forastiere A, Cooper J, Maor M, Goepfert H, et al.
Outcome of salvage total laryngectomy following organ preservation
therapy: the radiation therapy oncology group trial 91-11. Arch Otolaryngol
Head Neck Surg. 2003;129:44–9.
11. Lin Y-C, Hsiao J-R, Tsai S-T. Salvage surgery as the primary treatment for
recurrent oral squamous cell carcinoma. Oral Oncol. 2004;40:183–9.
12. Sorensen LD, McCarthy M, Baumgartner MB, Demars CS. Perioperative
immunonutrition in head and neck cancer. Laryngoscope. 2009;119:1358–64.
13. Bharadwaj S, Trivax B, Tandon P, Alkam B, Hanouneh I, Steiger E. Should
perioperative immunonutrition for elective surgery be the current standard
of care? Gastroenterol Rep. 2016;4:87–95.
14. Hurwitz AA, Watkins SK. Immune suppression in the tumor
microenvironment: a role for dendritic cell-mediated tolerization of T cells.
Cancer Immunol Immunother. 2012;61:289–93.
15. Alazawi W, Pirmadjid N, Lahiri R, Bhattacharya S. Inflammatory and immune
responses to surgery and their clinical impact. Ann Surg. 2016;264:73–80.
16. Marimuthu K, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of the
effect of combinations of immune modulating nutrients on outcome in
patients undergoing major open gastrointestinal surgery. Ann Surg. 2012;
255:1060–8.
17. Zhang Y, Gu Y, Guo T, Li Y, Cai H. Perioperative immunonutrition for
gastrointestinal cancer: a systematic review of randomized controlled trials.
Surg Oncol. 2012;21:e87–95.
18. Aeberhard C, Mayer C, Meyer S, Mueller SA, Schuetz P, Stanga Z, et al. Effect
of preoperative immunonutrition on postoperative short-term outcomes of
patients with head and neck squamous cell carcinoma. Head Neck. 2018;40:
1057–67.
19. Felekis D, Eleftheriadou A, Papadakos G, Bosinakou I, Ferekidou E, Kandiloros
D, et al. Effect of perioperative immuno-enhanced enteral nutrition on
Mueller et al. Journal of Otolaryngology - Head and Neck Surgery           (2019) 48:25 Page 8 of 9
inflammatory response, nutritional status, and outcomes in head and neck
cancer patients undergoing major surgery. Nutr Cancer. 2010;62:1105–12.
20. Snyderman CH, Kachman K, Molseed L, Wagner R, D’Amico F, Bumpous J,
et al. Reduced postoperative infections with an immune-enhancing
nutritional supplement. Laryngoscope. 1999;109:915–21.
21. Turnock A, Calder PC, West AL, Izzard M, Morton RP, Plank LD. Perioperative
immunonutrition in well-nourished patients undergoing surgery for head
and neck cancer: evaluation of inflammatory and immunologic outcomes.
Nutrients. 2013;5:1186–99.
22. Falewee MN, Schilf A, Boufflers E, Cartier C, Bachmann P, Pressoir M, et al.
Reduced infections with perioperative immunonutrition in head and neck
cancer: exploratory results of a multicenter, prospective, randomized,
double-blind study. Clin Nutr. 2014;33:776–84.
23. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z. Ad hoc ESPEN working
group. Nutritional risk screening (NRS 2002): a new method based on an
analysis of controlled clinical trials. Clin Nutr. 2003;22:321–36.
24. Sobin LH, Gospodarowicz MK. Wittekind C. TNM classification of malignant
tumours. 7th ed. Hoboken: Wiley-Blackwell; 2009.
25. Alexander JW, Supp DM. Role of arginine and Omega-3 fatty acids in
wound healing and infection. Adv wound care. 2014;3:682–90.
26. Evans RW, Fernstrom JD, Thompson J, Morris SM, Kuller LH. Biochemical
responses of healthy subjects during dietary supplementation with L-
arginine. J Nutr Biochem. 2004;15:534–9.
27. Buzby GP, Knox LS, Crosby LO, Eisenberg JM, Haakenson CM, McNeal GE,
et al. Study protocol: a randomized clinical trial of total parenteral nutrition
in malnourished surgical patients. Am J Clin Nutr. 1988;47(2 Suppl):366–81.
28. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications:
a new proposal with evaluation in a cohort of 6336 patients and results of a
survey. Ann Surg. 2004;240:205–13.
29. de Luis DA, Izaola O, Cuellar MC, Terroba T, Aller R. High dose of arginine
enhanced enteral nutrition in postsurgical head and neck cancer patients.
A randomized clinical trial. Eur Rev Med Pharmacol Sci. 2009;13:279–83.
30. de Luis DA, Izaola O, Cuellar L, Terroba MC, Aller R. Randomized clinical trial
with an enteral arginine-enhanced formula in early postsurgical head and
neck cancer patients. Eur J Clin Nutr. 2004;58:1505–8.
31. de Luis D, Aller R, Izaola O, Cuellar L, Terroba M. Postsurgery enteral
nutrition in head and neck cancer patients. Eur J Clin Nutr. 2002;56:1126–9.
32. van Bokhorst-De Van Der Schueren MA, Quak JJ, von Blomberg-van der
Flier BM, Kuik DJ, Langendoen SI, Snow GB, et al. Effect of perioperative
nutrition, with and without arginine supplementation, on nutritional
status, immune function, postoperative morbidity, and survival in
severely malnourished head and neck cancer patients. Am J Clin Nutr.
2001;73:323–32.
33. Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN
guideline: Clinical nutrition in surgery. Clin Nutr. 2017;36:623–50.
34. McClave SA, Martindale RG, Vanek VW, McCarthy M, Roberts P, Taylor B,
et al. Guidelines for the provision and assessment of nutrition support
therapy in the adult critically ill patient. J Parenter Enter Nutr. 2009;33:
277–316.
35. Stableforth WD, Thomas S, Lewis SJ. A systematic review of the role of
immunonutrition in patients undergoing surgery for head and neck cancer.
Int J Oral Maxillofac Surg. 2009;38:103–10.
36. Riso S, Aluffi P, Brugnani M, Farinetti F, Pia F, D’Andrea F. Postoperative
enteral immunonutrition in head and neck cancer patients. Clin Nutr. 2000;
19:407–12.
37. de Luis DA, Izaola O, Cuellar L, Terroba MC, Martin T, Aller R. Clinical and
biochemical outcomes after a randomized trial with a high dose of enteral
arginine formula in postsurgical head and neck cancer patients. Eur J Clin
Nutr. 2007;61:200–4.
38. de Luis DA, Izaola O, Aller R, Cuellar L, Terroba MC. A randomized clinical
trial with oral Immunonutrition (omega3-enhanced formula vs. arginine-
enhanced formula) in ambulatory head and neck cancer patients. Ann Nutr
Metab. 2005;49:95–9.
39. Denham JW, Hauer-Jensen M. The radiotherapeutic injury – a complex
‘wound’. Radiother Oncol. 2002;63:129–45.
40. Miller SH, Rudolph R. Healing in the irradiated wound. Clin Plast Surg. 1990;
17:503–8.
41. Olascoaga A, Vilar-Compte D, Poitevin-Chacón A, Contreras-Ruiz J. Wound
healing in radiated skin: pathophysiology and treatment options. Int Wound
J. 2008;5:246–57.
42. Tibbs MK. Wound healing following radiation therapy: a review. Radiother
Oncol. 1997;42:99–106.
43. Popovic PJ, Zeh HJ, Ochoa JB. Arginine and immunity. J Nutr. 2007;137(6
Suppl 2):1681S–6S.
44. Bronte V, Zanovello P. Regulation of immune responses by L-arginine
metabolism. Nat Rev Immunol. 2005;5:641–54.
45. Wu G, Bazer FW, Burghardt RC, Johnson GA, Kim SW, Knabe DA, et al.
Proline and hydroxyproline metabolism: implications for animal and human
nutrition. Amino Acids. 2011;40:1053–63.
46. Barbul A. Proline precursors to sustain mammalian collagen synthesis.
J Nutr. 2008;138:2021S–4S.
Mueller et al. Journal of Otolaryngology - Head and Neck Surgery           (2019) 48:25 Page 9 of 9
